Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MediReg
- Development stage
- Phase 2
- Lead developer
- Lomonosov Moscow State University
- Modality
- Cell Therapies
- Administration
- Parenteral
01
Overview
MediReg is a biologic medicinal product composed of the secretome of human mesenchymal stromal cells (hMSCs), provided as a lyophilizate for the preparation of an injectable solution. It is being developed for the treatment of severe male infertility, including non-obstructive azoospermia and severe oligoasthenoteratozoospermia (OAT). The drug is administered via a single injection into the testes to improve spermatogenesis and sperm quality, potentially increasing the success of assisted reproductive technologies. The Phase I/II clinical trial is conducted by Lomonosov Moscow State University.
- Brand names
- MediReg
- Other names
- Human Mesenchymal Stromal Cell SecretomehMSC secretome
Beyond the preview
Go deeper on MediReg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MediReg.